VCU
VCU
Publications
30
Total Publications
6
Abstract/Manuscript
1
Oral Presentation
23
Poster Presentation
2025 · Abstract/Manuscript · UNC
The Magnitude of Polypharmacy and Role of Disease Severity and Patient Sex in Medication Use Among Patients With MASLD Enrolled in TARGET-NASH
Read more →2025 · Abstract/Manuscript · Kings College of London
Cardiovascular risk assessment tools are insufficient for patients with metabolic dysfunction associated steatotic liver disease
Read more →2025 · Poster Presentation · Saint Louis University · Hepatology
Clinical Characteristics of Patients With Presumed MASLD Who Meet Met-ALD Criteria in the TARGET-NASH Cohort
Read more →2025 · Poster Presentation · Madrigal · Hepatology
Relationship between non-invasive tests, clinical outcomes and liver biopsy among people with MASH under real-world conditions
Read more →2024 · Poster Presentation · University of Birmingham UK · Hepatology
Stability of the NASH-CHECK patient-reported outcome measure over time in patients with metabolic dysfunction-associated steatotic liver disease and stable clinical status
Read more →2024 · Poster Presentation · UNC · Hepatology
A prospective assessment of the impact of decompensation of cirrhosis on patient-reported outcomes in metabolic dysfunction-associated steatotic liver disease
Read more →2024 · Poster Presentation · Merck · Hepatology
Time to Disease Progression and All-Cause Mortality in Adult MASH Patients in Real-World US Cohort
Read more →2024 · Poster Presentation · Merck · Hepatology
Characteristics of adult MASH patients and factors associated with MASH-relevant clinical endpoints in a real-world US cohort
Read more →2024 · Poster Presentation · University of Birmingham UK · Hepatology
Real-World Use of Glucagon-Like Peptide 1 Receptor Agonists in Patients with MASLD: A Cross-Sectional Analysis from TARGET-NASH
Read more →2024 · Poster Presentation · Saint Louis University · Hepatology
A prospective assessment of disease progression impact on patient-reported outcomes in metabolic dysfunction-associated steatotic liver disease
Read more →2024 · Poster Presentation · Heinrich Heine University Düsseldorf · Hepatology
Relationship between liver biopsy fibrosis stage and clinical outcomes among persons with MASLD/MASH
Read more →2024 · Oral Presentation · Saint Louis University · Hepatology
Use of glucagon-like peptide 1 receptor agonists in patients with MASLD in a real-world setting is associated with slower disease progression and lower all-cause mortality
Read more →2023 · Abstract/Manuscript · National University Hospital
Validation of a Clinical Risk-based Classification System in a Large Nonalcoholic Fatty Liver Disease Real-world Cohort
Read more →2022 · Poster Presentation · Novartis · Hepatology
Longitudinal ALT Trajectories are Generally Stable Among Patients with Non-Alcoholic Fatty Liver Disease (NAFLD): An Investigation Using Artificial Recurrent Neural Networks
Read more →2021 · Poster Presentation · AbbVie · Hepatology
Determination of Optimal Thresholds for Significant Fibrosis in NAFLD Using Non-Invasive Tests from TARGET-NASH Study
Read more →2021 · Abstract/Manuscript · Heinrich Heine University Düsseldorf
Liver Biopsy in the Real World—Reporting, Expert Concordance and Correlation with a Pragmatic Clinical Diagnosis
Read more →2020 · Poster Presentation · University of Miami (FL) · Hepatology
A Pragmatic Clinical Prognostic Classification Suitable for Universal Application Stratifies Patients with NAFLD by Risk of Mortality and Both Hepatic and Extrahepatic Outcomes
Read more →2020 · Poster Presentation · Heinrich-Heine University Düsseldorf · Hepatology
Heterogeneous Documentation and Poor Concordance of NASH Pathology May Limit its Clinical Utility in Real-World Practice
Read more →2020 · Poster Presentation · UNC · Hepatology
Fibrosis Assessed by Non-Invasive Tests is Similar to Liver Biopsy for Predicting Clinical Outcomes: A TARGET-NASH Study
Read more →2020 · Poster Presentation · Novartis · Hepatology
Predicting advanced fibrosis using non-invasive clinical tests and modern machine learning methods in TARGET-NASH
Read more →2020 · Abstract/Manuscript · University of Michigan
A Real-World Observational Cohort of Patients with Hepatocellular Carcinoma: Design and Rationale for TARGET-HCC
Read more →2019 · Poster Presentation · University of Michigan · Hepatology
Routinely Available Noninvasive Tests Perform Well in Identifying Patients with Advanced Fibrosis Due to NASH: Data from the TARGET-NASH Observational Cohort
Read more →2019 · Poster Presentation · Emory · Hepatology
Patterns of Medication Use Among Adult Patients with Elevated Serum ALT Levels in Patients with NAFLD: TARGET-NASH
Read more →2019 · Poster Presentation · Saint Louis University · Hepatology
Management of Hepatocellular Carcinoma (HCC) in a Real Life Multinational, Longitudinal, Observational Study (TARGET-HCC)
Read more →2019 · Poster Presentation · Saint Louis University · Hepatology
Regional, racial/ethnic, and socioeconomic disparities and treatment outcomes in patients with hepatocellular carcinoma (HCC) in the US
Read more →2018 · Poster Presentation · University of Michigan · Hepatology
Nonalcoholic Fatty Liver Disease in Children in the U.S.: Clinical Characteristics of Participants Enrolled in TARGET-NASH
Read more →2018 · Poster Presentation · University of Michigan · Hepatology
Real World Evidence Showing High Rates of Cardiovascular Events in NAFLD Patients Regardless of Liver Disease (DDW)
Read more →2017 · Poster Presentation · University of Michigan · Hepatology
Sustained Elevation in Alkaline Phosphatase is Associated with Greater Disease Severity in Real World NAFLD in TARGET-NASH
Read more →2017 · Poster Presentation · University of Michigan · Hepatology